Literature DB >> 19255110

Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States.

Nila J Dharan1, Larisa V Gubareva, John J Meyer, Margaret Okomo-Adhiambo, Reginald C McClinton, Steven A Marshall, Kirsten St George, Scott Epperson, Lynnette Brammer, Alexander I Klimov, Joseph S Bresee, Alicia M Fry.   

Abstract

CONTEXT: During the 2007-2008 influenza season, oseltamivir resistance among influenza A(H1N1) viruses increased significantly for the first time worldwide. Early surveillance data suggest that the prevalence of oseltamivir resistance among A(H1N1) viruses will most likely be higher during the 2008-2009 season.
OBJECTIVES: To describe patients infected with oseltamivir-resistant influenza A(H1N1) virus and to determine whether there were any differences between these patients and patients infected with oseltamivir-susceptible A(H1N1) virus in demographic or epidemiological characteristics, clinical symptoms, severity of illness, or clinical outcomes. DESIGN, SETTING, AND PATIENTS: Influenza A(H1N1) viruses that were identified and submitted to the Centers for Disease Control and Prevention by US public health laboratories between September 30, 2007, and May 17, 2008, and between September 28, 2008, and February 19, 2009, were tested as part of ongoing surveillance. Oseltamivir resistance was determined by neuraminidase inhibition assay and pyrosequencing analysis. Information was collected using a standardized case form from patients with oseltamivir-resistant A(H1N1) infections and a comparison group of patients with oseltamivir-susceptible A(H1N1) infections during 2007-2008. MAIN OUTCOME MEASURES: Demographic and epidemiological information as well as clinical information, including symptoms, severity of illness, and clinical outcomes.
RESULTS: During the 2007-2008 season, influenza A(H1N1) accounted for an estimated 19% of circulating influenza viruses in the United States. Among 1155 influenza A(H1N1) viruses tested from 45 states, 142 (12.3%) from 24 states were resistant to oseltamivir. Data were available for 99 oseltamivir-resistant cases and 182 oseltamivir-susceptible cases from this period. Among resistant cases, median age was 19 years (range, 1 month to 62 years), 5 patients (5%) were hospitalized, and 4 patients (4%) died. None reported oseltamivir exposure before influenza diagnostic sample collection. No significant differences were found between cases of oseltamivir-resistant and oseltamivir-susceptible influenza in demographic characteristics, underlying medical illness, or clinical symptoms. Preliminary data from the 2008-2009 influenza season identified resistance to oseltamivir among 264 of 268 influenza A(H1N1) viruses (98.5%) tested.
CONCLUSIONS: Oseltamivir-resistant A(H1N1) viruses circulated widely in the United States during the 2007-2008 influenza season, appeared to be unrelated to oseltamivir use, and appeared to cause illness similar to oseltamivir-susceptible A(H1N1) viruses. Circulation of oseltamivir-resistant A(H1N1) viruses will continue, with a higher prevalence of resistance, during the 2008-2009 season.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255110     DOI: 10.1001/jama.2009.294

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  230 in total

1.  The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses.

Authors:  Wai Lan Wu; Siu-Ying Lau; Yixin Chen; Genyan Wang; Bobo Wing-Yee Mok; Xi Wen; Pui Wang; Wenjun Song; Tianwei Lin; Kwok-Hung Chan; Kwok-Yung Yuen; Honglin Chen
Journal:  Antiviral Res       Date:  2011-11-25       Impact factor: 5.970

2.  During influenza season, which children need an antiviral and which one should I prescribe? Do I need to verify that they have influenza first?

Authors:  M Bowman; Se Forgie
Journal:  Paediatr Child Health       Date:  2010-10       Impact factor: 2.253

3.  Targeting of the influenza A virus polymerase PB1-PB2 interface indicates strain-specific assembly differences.

Authors:  Peter Reuther; Benjamin Mänz; Linda Brunotte; Martin Schwemmle; Kerstin Wunderlich
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

Review 4.  The 2009 influenza A (H1N1) pandemic: what have we learned in the past 6 months.

Authors:  Carlos del Rio; Jeannette Guarner
Journal:  Trans Am Clin Climatol Assoc       Date:  2010

Review 5.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

6.  Impact of precautionary behaviors during outbreaks of pandemic influenza: modeling of regional differences.

Authors:  Joakim Ekberg; Henrik Eriksson; Magnus Morin; Einar Holm; Magnus Strömgren; Toomas Timpka
Journal:  AMIA Annu Symp Proc       Date:  2009-11-14

Review 7.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

8.  [Antivirals and pandemic flu].

Authors:  José María Eiros Bouza; Alberto Pérez Rubio; Javier Castrodeza Sanz
Journal:  Aten Primaria       Date:  2010-06-16       Impact factor: 1.137

9.  Sphingosine 1-phosphate-metabolizing enzymes control influenza virus propagation and viral cytopathogenicity.

Authors:  Young-Jin Seo; Celeste Blake; Stephen Alexander; Bumsuk Hahm
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

Review 10.  Detection and management of antiviral resistance for influenza viruses.

Authors:  Guy Boivin
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.